Author:
Piessevaux H.,Buyse M.,De Roock W.,Prenen H.,Schlichting M.,Van Cutsem E.,Tejpar S.
Funder
Promotion of Innovation by Science and Technology in Flanders
Reference16 articles.
1. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab;De Roock;Ann Oncol,2008
2. Role of KRAS mutation in predicting response, progression-free survival, and overall survival in irinotecan-refractory patients treated with cetuximab plus irinotecan for a metastatic colorectal cancer: analysis of 281 individual data from published series;Di Fiore;J Clin Oncol,2008
3. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab;Lièvre;J Clin Oncol,2008
4. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience;Van Cutsem;J Clin Oncol,2008
5. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer;Amado;J Clin Oncol,2008
Cited by
67 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献